Mycoses – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Mycoses – Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mycoses and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mycoses
- The report reviews pipeline therapeutics for Mycoses by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mycoses therapeutics and enlists all their major and minor projects
- The report assesses Mycoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mycoses
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mycoses
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mycoses pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
60 Degrees Pharmaceuticals IncAbGenics Life Sciences Pvt Ltd
AimMax Therapeutics Inc
AJK Biopharmaceutical LLC
Almirall SA
Amtixbio Co Ltd
ASCIL Biopharm
Astellas Pharma Inc
Autoimmune Technologies LLC
Bakker Medical Srl
Basilea Pharmaceutica Ltd
Beta Pharma Inc
Biocidium Biopharmaceuticals Inc
Biokawthar Technologies SAS
Biomendics LLC
Biosergen AS
Blueberry Therapeutics Ltd
Bright Angel Therapeutics
Cellix Bio Pvt Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
China Medical System Holdings Ltd
Cidara Therapeutics Inc
Cincinnati Children's Hospital Medical Center
Cisen Pharmaceutical Co Ltd
Collaborations Pharmaceuticals Inc
Concerto Biosciences Inc
Crystec Ltd
CSA Biotechnologies LLC
CSPC Pharmaceutical Group Ltd
Curatix LLC
Dare Bioscience Inc
Demuris Ltd
DermBiont Inc
Destiny Pharma Plc
Diatheva srl
Eisai Co Ltd
EpiPharma Drug Development LLC
Evoq Nano Inc
Exopharm Ltd
F2G Ltd
Female Healthcare Purna
Fondation MEDINA
Foundation For Neglected Disease Research
Gedeon Richter Plc
General Biologicals Corp
George Papanicolaou Hospital
Georgetown University
Grupo Ferrer Internacional SA
Hallux Inc
HC Synthetic Pharmaceutical Co Ltd
Immunitor Inc
Immupharma Plc
Innovation Pharmaceuticals Inc
IntronX Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu ProteLight Pharmaceutical & Biotechnology Co Ltd
Kamat Pharmatech LLC
Kansas State University
Kathera Bioscience Inc
King's College London
Lakewood-Amedex Inc
Louisiana State University Health Sciences Center New Orleans
Matinas BioPharma Holdings Inc
Maxwell Biosciences Inc
Merck & Co Inc
MicroRid Technologies Inc
Moberg Pharma AB
Molecular Express Inc
Mycovia Pharmaceuticals Inc
NAL Pharmaceuticals Ltd
Nanomerics Ltd
Nektr Technologies Ltd
Next Science Ltd
Nob Hill Therapeutics Inc
Nosopharm SAS
Omnix Medical Ltd
Opal Biosciences Ltd
Oryn Therapeutics
Osel Inc
Pacgen Life Science Corp
Panjab University
Pfizer Inc
Photonamic GmbH & Co KG
Profem GmbH
Profounda Inc
Pulmatrix Inc
Pulmocide Ltd
Pulmonomy Inc
Quercus Molecular Design LLC
R-Pharm
Regeneron Pharmaceuticals Inc
REYON Pharmaceutical Co Ltd
Riptide Bioscience Inc
Sano Chemicals Inc
SaNOtize Research and Development Corp
Satellos Bioscience Inc
Scynexis Inc
Second Military Medical University
Seren Pharmaceuticals Inc
Shandong Dyne Marine Biopharmaceutical Co Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Sinsin Pharmaceutical Co Ltd
Sisu Pharma Inc
Stadius Biopharma LLC
State University of New York at Buffalo
Stony Brook University
Taro Pharmaceuticals USA Inc
TFF Pharmaceuticals Inc
The Lundquist Institute
The University of Manchester
The Walter and Eliza Hall Institute of Medical Research
Tianjin Institute of Pharmaceutical Research
TIPR-HUYA Advancing Innovative Medicines
Toltec Pharmaceuticals LLC
Trilogy Therapeutics Inc
TTY Biopharm Co Ltd
Turn Therapeutics Inc
University of Aberdeen
University of California San Diego
University of Debrecen
University of Pittsburgh
University of Toulouse
University of Wisconsin Madison
Vyome Therapeutics Inc
Wellstat Vaccines LLC
ZabBio Inc
Zentek Ltd